LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

YS 10.29.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur YS Tweets

About Gravity Analytica

Recent News

  • 12.19.2024 - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
  • 12.13.2024 - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
  • 11.07.2024 - LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

Recent Filings

  • 12.19.2024 - EX-99.1 EX-99.1
  • 12.19.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]

GAITHERSBURG, Md.,Oct. 29, 2024/PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it has received a written notice (the "Compliance Notice") from the Listing Qualifications Department ofThe Nasdaq Stock Market LLC("Nasdaq") datedOctober 21, 2024, informing the Company that it has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").

(PRNewsfoto/YS Biopharma Co., Ltd.)

As previously announced, the Company was notified by Nasdaq onOctober 24, 2023that the Company was not in compliance with the Minimum Bid Price Requirement as the closing bid price of the Company's ordinary shares was below$1.00per share for a period of 30 consecutive business days.

According to the Compliance Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company's ordinary shares have been$1.00per share or greater for 11 consecutive business days, fromOctober 4, 2024, toOctober 18, 2024, and the matter is now closed.

About LakeShore Biopharma

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The Company operates inChina,the United States,Singapore, andthe Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visitinvestor.lakeshorebio.com.

Investor Relations Contact

Robin YangPartner,ICR, LLCTel: +1 (212) 537-4035Email:LakeShoreBiopharma.IR@icrinc.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/lakeshore-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302289990.html

SOURCELakeShore Biopharma Co., Ltd

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com